Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

Multiple Sclerosis

Volumn 21, Issue 8, 2015, Pages 1036-1044

  Warnke, Clemens ^a   Stettner, Mark ^a   Lehmensiek, Vera ^b   Dehmel, Thomas ^a   Mausberg, Anne K ^a   Von Geldern, Gloria ^c   Gold, Ralf ^d   Kümpfel, Tania ^e   Hohlfeld, Reinhard ^e   Mäurer, Mathias ^f   Stangel, Martin ^g   Straeten, Vera ^h   Limmroth, Volker ⁱ   Weber, Thomas ^j   Kleinschnitz, Christoph ^k   Wattjes, Mike P ^l   Svenningsson, Anders ^m   Olsson, Tomas ⁿ   Hartung, Hans Peter ^a   Hermsen, Derik ^o   Tumani, Hayrettin ^b   Adams, Ortwin ^a,p   Kieseier, Bernd C ^a   more..

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f CARITAS KRANKENHAUS   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h KLINIKUM MINDEN   (Germany)

ⁱ KRANKENHAUS MERHEIM   (Germany)

^j Marienhospital Hamburg   (Germany)

^k UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁿ KAROLINSKA INSTITUTE   (Sweden)

^o UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^p Department of Orthopedic Surgery   (Germany)

more..

Author keywords

disease modifying therapies; immunosuppression; JC virus; multiple sclerosis; natalizumab; Progressive multifocal leukoencephalopathy; Tysabri

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NATALIZUMAB; OLIGOCLONAL BAND; CD19 ANTIGEN; IMMUNOLOGIC FACTOR; CD14 ANTIGEN; CD3 ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CD19+ B LYMPHOCYTE; CELL COMPOSITION; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; T LYMPHOCYTE; TREATMENT DURATION; YOUNG ADULT; BLOOD; CD4 CD8 RATIO; CEREBROSPINAL FLUID; DRUG EFFECTS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; CELL FUNCTION; CELLULAR PARAMETERS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOBLOTTING; ISOELECTRIC FOCUSING; NEPHELOMETRY; POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; AGED; ANTIGENS, CD19; B-LYMPHOCYTES; CD4-CD8 RATIO; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; OLIGOCLONAL BANDS; YOUNG ADULT;

EID: 84985914372     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514556296     Document Type: Article

References (40)

1. Yednock TA, Cannon C, Fritz LC,. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
2. del Pilar Martin M, Cravens PD,. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65: 1596-1603.
3. Stuve O, Marra CM, Jerome KR,. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59: 743-747.
4. Warnke C, Mausberg AK, Stettner M,. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 2013; 81: 1400-1408.
5. Zohren F, Toutzaris D, Klarner V,. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893-3895.
6. Krumbholz M, Meinl I, Kumpfel T,. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350-1354.
7. Planas R, Jelcic I, Schippling S,. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012; 42: 790-798.
8. Saure C, Warnke C, Zohren F,. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 2011; 68: 1428-1431.
9. Jing D, Oelschlaegel U, Ordemann R,. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010; 45: 1489-1496.
10. Koopman G, Keehnen RM, Pals ST,. Interaction through the LFA-1/ICAM-1 pathway prevents programmed cell death of germinal center B cells. Adv Exp Med Biol 1993; 329: 387-392.
11. Bloomgren G, Richman S, Hotermans C,. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
12. Warnke C, Menge T, Hartung HP,. Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided? Arch Neurol 2010; 67: 923-930.
13. Fine AJ, Sorbello A, Kortepeter C,. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 2013; 57: 849-852.
14. Warnke C, Ramanujam R, Plavina T,. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1199-1205.
15. Selter RC, Biberacher V, Grummel V,. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler 2013; 19: 1454-1461.
16. Mancuso R, Franciotta D, Rovaris M,. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study. Mult Scler 2014; In press.
17. Harrer A, Tumani H, Niendorf S,. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler 2013; 19: 1209-1212.
18. Warnke C, von Geldern G, Markwerth P,. The CSF JCV antibody index for diagnosis of natalizumab-associated PML. Ann Neurol 2014; In press.
19. Keir G, Luxton RW, Thompson EJ,. Isoelectric focusing of cerebrospinal fluid immunoglobulin G: An annotated update. Ann Clin Biochem 1990; 27: 436-443.
20. Andersson M, Alvarez-Cermeno J, Bernardi G,. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897-902.
21. Reiber H, Peter JB,. Cerebrospinal fluid analysis: Disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184: 101-122.
22. Reiber H, Ungefehr S, Jacobi C,. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4: 111-117.
23. Leite RP, Carmo-Fonseca M, Cabecadas J,. Differential expression of cell adhesion molecules in the functional compartments of lymph nodes and tonsils. Clin Mol Pathol 1995; 48: M93-M100.
24. von Andrian UH, Engelhardt B,. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72.
25. Koopman G, Keehnen RM, Lindhout E,. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994; 152: 3760-3767.
26. Serafini B, Rosicarelli B, Magliozzi R,. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164-174.
27. Harrer A, Wipfler P, Einhaeupl M,. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. J Neuroimmunol 2011; 234: 148-154.
28. Lindberg RL, Achtnichts L, Hoffmann F,. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194: 153-164.
29. Meira M, Sievers C, Hoffmann F,. MiR-126: A novel route for natalizumab action? Mult Scler 2014; 20: 1363-1370.
30. Marshall LJ, Ferenczy MW, Daley EL,. Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol 2014; 88: 5177-5183.
31. Houff SA, Berger J, Major EO,. Response to Linberg et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 204: 155-156; author reply 157.
32. Warnke C, Smolianov V, Dehmel T,. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2011; 17: 151-156.
33. Frohman EM, Monaco MC, Remington G,. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014; 71: 596-602.
34. Chalkias S, Dang X, Bord E,. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 2014; 75: 925-934.
35. Skarica M, Eckstein C, Whartenby KA,. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 2011; 235: 70-76.
36. Reid CE, Li H, Sur G,. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 2011; 204: 237-244.
37. Gorelik L, Reid C, Testa M,. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 2011; 204: 103-114.
38. Bayliss J, Karasoulos T, McLean CA,. Frequency and large T (LT) sequence of JC polyomavirus DNA in oligodendrocytes, astrocytes and granular cells in non-PML brain. Brain Pathol 2012; 22: 329-336.
39. Sundqvist E, Buck D, Warnke C,. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 2014; 10: e1004084.
40. Plavina T, Carulli J, Li H,. B cell-specific signal in whole blood and serum of natalizumab-treated PML patients is revealed using transcript and protein profiling. Neurology 2014; 82: Supplement S31. 004.